Drug-Induced Cholestasis

Mechanisms and Risk Factors

• Drug-induced cholestasis occurs through two major mechanisms: inhibition of hepatocellular transporters and idiosyncratic inflammatory/hypersensitive reactions, affecting bile secretion at the hepatocellular and bile ductular/cholangiocellular levels, respectively 1, 2
• Age, gender, medication dosage, and co-administered medications increase susceptibility to drug-induced cholestasis 1, 2
• Rifampicin can cause hepatitis, sometimes with cholestasis, and isoniazid can produce hepatitis with hepatocellular damage seldom associated with cholestasis when used simultaneously with rifampicin 3

Diagnosis and Management

• Diagnosis of drug-induced cholestasis is based on the temporal relationship between drug intake and onset of cholestasis, characterized by elevated alkaline phosphatase (AP) >2 ULN or ALT/AP ratio <2, and requires exclusion of other causes of cholestasis 4, 1, 5, 6
• The only effective treatment is withdrawal of the suspected drug, and early detection of abnormal liver tests and prompt drug withdrawal are crucial 4, 2
• Ursodeoxycholic acid (UDCA) may beneficially affect cholestasis in approximately two-thirds of cases, but evidence is limited 4, 2
• Monitor liver function tests carefully when prescribing medications known to cause cholestasis, especially in patients with pre-existing liver conditions 7

Clinical Course and Prognosis

• The outcome after drug withdrawal is generally good in most cases, with drug-induced cholestatic injury having a better prognosis than hepatocellular injury 4, 2, 5, 6
• Drug-induced cholestasis accounts for approximately 30% of drug-induced liver injury (DILI) cases, with a prevalence estimated between 1 in 10,000 and 1 in 100,000 patients, though this is likely underreported 1, 2, 5, 6

Treatment of Cholestatic Drug-Induced Liver Injury

Diagnosis and Management

• The American Gastroenterological Association recommends ruling out autoimmune features, such as normal autoimmune markers (ANA, ASMA) and normal IgG levels, to exclude drug-induced autoimmune-like hepatitis or overlap syndromes that might require different management 8, 9
• The European Association for the Study of the Liver suggests considering ursodeoxycholic acid (UDCA) 13-15 mg/kg/day for cholestatic DILI, as it may beneficially affect cholestasis in approximately two-thirds of cases 8

Adjunctive Pharmacotherapy

• The American Association for the Study of Liver Diseases recommends against using corticosteroids or immunosuppressive therapy in cholestatic DILI with normal autoimmune markers and IgG levels, except in cases with elevated IgG >2× ULN and/or anti-smooth muscle antibody titers >1:80 8, 9

Monitoring Strategy

• The American College of Gastroenterology recommends repeating liver function tests within 7-10 days after drug discontinuation to confirm cholestatic pattern and assess trend, and continuing monitoring until alkaline phosphatase normalizes or returns to baseline, total bilirubin normalizes, and clinical symptoms resolve 8, 9

Clinical Pitfalls to Avoid

• The European Association for the Study of the Liver warns against confusing cholestatic DILI with drug-induced autoimmune-like hepatitis, which presents with elevated aminotransferases >5× ULN, positive autoantibodies, elevated IgG, and may require corticosteroids 8, 9

Management of Drug‑Induced Cholestatic Liver Injury

Primary Management – Immediate Drug Withdrawal

• Prompt cessation of the suspected hepatotoxic agent prevents irreversible liver failure, vanishing bile‑duct syndrome, and progression to biliary cirrhosis. 10
• Immediate drug withdrawal is the only proven intervention that halts progression to severe liver damage or death in drug‑induced cholestatic injury. 10
• Early detection of abnormal liver tests followed by immediate drug discontinuation is essential to avoid serious injury and the need for liver transplantation. 10

Adjunctive Pharmacotherapy – Ursodeoxycholic Acid (UDCA)

• UDCA administered at 13–15 mg/kg/day may improve cholestasis in roughly two‑thirds of patients, but the evidence is limited and the approach is considered experimental. The European Association for the Study of the Liver classifies this therapy as experimental (Level III/C2 evidence). 10
• When UDCA is used, it should be continued until liver enzymes have normalized, which typically occurs within three months in most cases. 10

Corticosteroids – Restricted Use

• Corticosteroids are not recommended for routine cholestatic DILI; they should be considered only in hypersensitivity‑mediated cholestasis with immunologic features (e.g., rash, fever, eosinophilia > 5 %). 10
• The supporting data for corticosteroid use are anecdotal, with no controlled trials available, indicating very low‑quality evidence. 10

Monitoring Protocol After Drug Withdrawal

• Liver function tests should be repeated 7–10 days after drug discontinuation to confirm the cholestatic pattern and assess trend. [11][12]
• Total bilirubin levels should be monitored until they return to baseline or normal range. 10
• Most patients achieve biochemical normalization within three months after drug cessation; however, a subset may develop prolonged cholestasis lasting more than six months, especially with agents such as chlorpromazine that can cause vanishing bile‑duct syndrome. 10

Indications for Liver Biopsy

• Liver biopsy is not mandatory for diagnosis but should be considered when:

Prognosis and Long‑Term Outcomes

• Mortality can reach up to 10 % in severe cases of cholestatic DILI. 10
• A minority of patients may exhibit persistent liver damage on follow‑up histology. 10
• Vanishing bile‑duct syndrome can lead to permanent liver injury and biliary cirrhosis. 10

Safety Considerations

• Re‑exposure (rechallenge) with the offending medication is contraindicated because it is potentially harmful, unethical, and not supported by clinical practice. 10